Keywords: edatrexate, combinations, cancer, researchers, memorial, sloan-kettering, center
EDATREXATE COMBINATIONS IN CANCER
Article | 31 May 1993
- Researchers at the Memorial Sloan-Kettering Cancer Center are testing combinations of Ciba's edatrexate with Bristol-Myers Squibb's Taxol (paclitaxel) and Rhone-Poulenc ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
